Roche enters partnership with the Global Fund to support low- and middle-income countries in strengthening critical diagnostics infrastructure

Almost half of the world ’s population has no or limited access to diagnosticsThis situation is especially acute in low- and middle-income countries (LMICs) where diagnostics plays a critical role for treating and containing the spread of infectious diseases such as Tuberculosis (TB) and HIVNew partnership between Roche and the Global Fund supports low- and middle-income countries in broadening access to diagnostics, helping millions of previously undiagnosed people with TB and HIV get diagnosed and eventually treatedBasel, 12 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY), through its Global Access Program, and The Global Fund to Fight AIDS, Tuberculosis and Malaria are joining forces to build and strengthen diagnostic capacity and pandemic preparedness in low-and middle-income countries fighting against HIV and tuberculosis (TB).About 2 billion people worldwide are estimated to be infected with tuberculosis, with 95% of TB deaths occurring in LMICs. Of more than 37 Million people living with HIV globally, over 6 Million people are undiagnosed. The COVID-19 pandemic has disrupted many HIV and TB programs, resulting in HIV testing rates falling by 22% and an estimated additional 100 000 deaths from tuberculosis in LMICs in 2020.1,2Roche and the Global Fund have joined forces to improve the diagnosis of HIV and TB in LMICs by building local capacity to tackle fundamental infrastructure challenges for generating and delivering diagnostic results and managing healthcare waste.T...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news